

REMARKS

Claims 1-14 and 17-18 are pending. Applicants elect Group II which is directed to a method of treating solid tumors in a patient. The pending claims are directed to the elected invention of using first and second agents. The nonelected inventions directed to a kit and a method of preparing a medicament are canceled without prejudice to their prosecution in a divisional application.

The amendments are fully supported by the original disclosure and, thus, no new matter is added by their entry. Swiss-format claims are reformatted as method of treatment claims.

Form PTO-1449 listing documents for the Examiner's consideration is attached. No fee is due because this Information Disclosure Statement is being submitted prior to a first Office Action on the merits. As provided by 37 CFR §§ 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all possible material information. Furthermore, no inference should be made that the cited documents are prior art merely because they have been submitted for consideration. Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited.

Applicants earnestly solicit an early and favorable examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /Gary R. Tanigawa/
Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100